scout
|Articles|May 1, 2008

Oncology NEWS International

  • Oncology NEWS International Vol 17 No 5
  • Volume 17
  • Issue 5

First trial of RXR agonist

IRVINE, California-NuRx Pharmaceuticals, Inc. has dosed the first patient in a single-center phase I clinical trial of its first-in-class rexinoid receptor (RXR) agonist NRX4204.

IRVINE, California-NuRx Pharmaceuticals, Inc. has dosed the first patient in a single-center phase I clinical trial of its first-in-class rexinoid receptor (RXR) agonist NRX4204. In preclinical studies, the orally bioavailable RXR agonist was effective in models of non-small-cell lung cancer and breast cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.


Latest CME